María Teresa Herrera-Abreu

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer”.

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1 -Mutant Breast Cancer

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1387

N/A

0DataRank · unranked

38 citations

Alex Pearson, María Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind Cutts, Heena Shah +12 more